Wednesday, July 8, 2026

Patent intelligence · US

US 11827883

Dosages and methods for delivering lipid formulated nucleic acid molecules

granted A61KA61K47/543A61K47/60A61K9/0019
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 17
Applicant portfolio 379
Patent details — US 11827883
Jurisdiction
US
Status
granted
Grant date
Nov 28, 2023
Expiration
Nov 23, 2043
Claims
40
CPC classes
A61K, A61K47/543, A61K47/60, A61K9/0019
View on Google Patents ↗

Quick answer

US 11827883 (Dosages and methods for delivering lipid formulated nucleic acid molecules) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
40
CPC classes
A61K, A61K47/543, A61K47/60, A61K9/0019, A61K9/1271, A61K9/1272

More from Alnylam Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Expires Sep 11, 2045

    granted
  2. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Expires Aug 28, 2045

    granted
  3. US 12397013

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385043

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  5. US 12385044

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  6. US 12378553

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 31, 2045

    granted
  7. US 12364762

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 17, 2045

    granted
  8. US 12350338

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 11827883?

US 11827883 (Dosages and methods for delivering lipid formulated nucleic acid molecules) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11827883?

Alnylam Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.

When does US 11827883 expire?

Our index shows an expiration date of Nov 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.